{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:48:18Z","timestamp":1790696898601,"version":"4.1.0"},"reference-count":161,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1016\/j.pharmthera.2012.04.003","type":"journal-article","created":{"date-parts":[[2012,6,22]],"date-time":"2012-06-22T17:16:23Z","timestamp":1340385383000},"page":"113-122","source":"Crossref","is-referenced-by-count":138,"title":["Cardiovascular side-effects of antipsychotic drugs: The role of the autonomic nervous system"],"prefix":"10.1016","volume":"135","author":[{"given":"Joanne Y.T.","family":"Leung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alasdair M.","family":"Barr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ric M.","family":"Procyshyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G.","family":"Honer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine C.Y.","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2012.04.003_bb0005","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/00004714-200102000-00003","article-title":"Effects of newer atypical antipsychotics on autonomic neurocardiac function: a comparison between amisulpride, olanzapine, sertindole, and clozapine","volume":"21","author":"Agelink","year":"2001","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0010","series-title":"AHA & NHLBI Scientific Statement","article-title":"Metabolic syndrome: new guidance for prevention and treatment","author":"AHA","year":"2005"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0015","doi-asserted-by":"crossref","first-page":"e22662","DOI":"10.1371\/journal.pone.0022662","article-title":"A double blind, placebo-controlled, randomized crossover study of the acute metabolic effects of olanzapine in healthy volunteers","volume":"6","author":"Albaugh","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0020","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1176\/ajp.156.11.1686","article-title":"Antipsychotic-induced weight gain: a comprehensive research synthesis","volume":"156","author":"Allison","year":"1999","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0025","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2174\/157488610789869265","article-title":"QT alterations in psychopharmacology: proven candidates and suspects","volume":"5","author":"Alvarez","year":"2010","journal-title":"Curr Drug Saf"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0030","doi-asserted-by":"crossref","first-page":"596","DOI":"10.2337\/diacare.27.2.596","article-title":"Consensus development conference on antipsychotic drugs and obesity and diabetes","volume":"27","author":"American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, & North American Association for the Study of Obesity","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0035","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/YCO.0b013e328314b74b","article-title":"Addressing cardiometabolic risk during treatment with antipsychotic medications","volume":"21","author":"Amiel","year":"2008","journal-title":"Curr Opin Psychiatry"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0040","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/bja\/71.5.736","article-title":"Effect of atropine on the QT interval and T-wave amplitude in healthy volunteers","volume":"71","author":"Annila","year":"1993","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0045","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1055\/s-2007-1000124","article-title":"Vascular effects of epinephrine, lisinopril, and chlorpromazine in diabetic and non-diabetic rats","volume":"15","author":"Aygit","year":"1999","journal-title":"J Reconstr Microsurg"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0050","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1161\/01.CIR.100.3.274","article-title":"Parasympathetic control of cardiac sympathetic activity: normal ventricular function versus congestive heart failure","volume":"100","author":"Azevedo","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0055","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1089\/met.2004.2.290","article-title":"The metabolic syndrome during atypical antipsychotic drug treatment: mechanisms and management","volume":"2","author":"Baptista","year":"2004","journal-title":"Metab Syndr Relat Disord"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0060","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2165\/00023210-200822060-00003","article-title":"Pharmacological management of atypical antipsychotic-induced weight gain","volume":"22","author":"Baptista","year":"2008","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0065","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1176\/appi.ps.62.6.682-a","article-title":"Excessive antipsychotic dosing in a Canadian outpatient population","volume":"62","author":"Barr","year":"2011","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0070","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.schres.2007.11.027","article-title":"Self-reported motivation to smoke in schizophrenia is related to antipsychotic drug treatment","volume":"100","author":"Barr","year":"2008","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0075","doi-asserted-by":"crossref","first-page":"R783","DOI":"10.1152\/ajpregu.00205.2011","article-title":"Adrenergic control of vascular resistance varies in muscles composed of different fiber types: influence of the vascular endothelium","volume":"301","author":"Behnke","year":"2011","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0080","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1080\/15622970701678815","article-title":"Myocarditis after overdose of conventional antipsychotics","volume":"10","author":"Bhatia","year":"2009","journal-title":"World J Biol Psychiatry"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0085","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11897-009-0003-y","article-title":"The conundrum of ventricular arrhythmia and cardiomyopathy: which abnormality came first?","volume":"6","author":"Bhushan","year":"2009","journal-title":"Curr Heart Fail Rep"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0090","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1161\/01.CIR.85.1.164","article-title":"Frequency domain measures of heart period variability and mortality after myocardial infarction","volume":"85","author":"Bigger","year":"1992","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0095","unstructured":"Boyda, H. N., Procyshyn, R. M., Tse, L., Hawkes, E., Jin, H., Pang, C. C. et al., (in press). Differential effects of three classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats. J Psychiatr Neurosci."},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0100","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/j.neuropharm.2011.02.019","article-title":"Intermittent treatment with olanzapine causes sensitization of the metabolic side-effects in rats","volume":"62","author":"Boyda","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0105","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.tips.2010.07.002","article-title":"Preclinical models of antipsychotic drug-induced metabolic side effects","volume":"31","author":"Boyda","year":"2010","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0110","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.pnpbp.2010.04.024","article-title":"A parametric study of the acute effects of antipsychotic drugs on glucose sensitivity in an animal model","volume":"34","author":"Boyda","year":"2010","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0115","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1080\/j.1440-1614.2005.01666_5.x","article-title":"Amisulpride and cardiomyopathy","volume":"39","author":"Brakoulias","year":"2005","journal-title":"Aust N Z J Psychiatry"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0120","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.schres.2009.12.016","article-title":"Prevalence of cardiovascular risk factors and disease in people with schizophrenia: a population-based study","volume":"117","author":"Bresee","year":"2010","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0125","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0893-133X(97)00073-0","article-title":"Effects of clozapine on plasma catecholamines and relation to treatment response in schizophrenia: a within-subject comparison with haloperidol","volume":"17","author":"Brown","year":"1997","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0130","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1192\/bjp.bp.109.067512","article-title":"Twenty-five year mortality of a community cohort with schizophrenia","volume":"196","author":"Brown","year":"2010","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0135","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2165\/00002018-200023030-00004","article-title":"Cardiovascular adverse effects of antipsychotic drugs","volume":"23","author":"Buckley","year":"2000","journal-title":"Drug Saf"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0140","first-page":"U2909","article-title":"Fatal cardiomyopathy due to quetiapine","volume":"121","author":"Bush","year":"2008","journal-title":"N Z Med J"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0145","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.pnpbp.2003.09.008","article-title":"Muscarinic mechanisms of antipsychotic atypicality","volume":"27","author":"Bymaster","year":"2003","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0150","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1001\/archpsyc.1982.04290100021004","article-title":"Plasma norepinephrine and dopamine-beta-hydroxylase activity in schizophrenia","volume":"39","author":"Castellani","year":"1982","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0155","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2165\/11599000-000000000-00000","article-title":"Drug treatment of obesity in cardiovascular disease","volume":"12","author":"Charakida","year":"2012","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0160","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/00004714-200006000-00004","article-title":"Anticholinergic differences among patients receiving standard clinical doses of olanzapine or clozapine","volume":"20","author":"Chengappa","year":"2000","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0165","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.schres.2008.12.012","article-title":"Insulin resistance and secretion in vivo: effects of different antipsychotics in an animal model","volume":"108","author":"Chintoh","year":"2009","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0170","first-page":"429","article-title":"Emerging role of sertindole in the management of schizophrenia","volume":"6","author":"Cincotta","year":"2010","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0175","first-page":"105","article-title":"Quetiapine-associated cardiomyopathy","volume":"124","author":"Coffey","year":"2011","journal-title":"N Z Med J"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0180","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1192\/bjp.179.2.167","article-title":"Association of autonomic dysfunction and clozapine. Heart rate variability and risk for sudden death in patients with schizophrenia on long-term psychotropic medication","volume":"179","author":"Cohen","year":"2001","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0185","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1136\/bmj.322.7296.1207","article-title":"Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study","volume":"322","author":"Coulter","year":"2001","journal-title":"BMJ"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0190","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1474-8673.1989.tb00480.x","article-title":"Effects of some antipsychotic drugs on cardiovascular catecholamine receptors in the rat","volume":"9","author":"Cuffi","year":"1989","journal-title":"J Auton Pharmacol"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0195","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0014-2999(89)90641-9","article-title":"Increased peripheral alpha 1-adrenoceptor sensitivity following chronic thioridazine treatment in the pithed rat","volume":"168","author":"Cuffi","year":"1989","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0200","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1517\/14656566.9.9.1451","article-title":"Antipsychotic-induced extrapyramidal symptoms and their management","volume":"9","author":"Dayalu","year":"2008","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0205","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/nrendo.2011.156","article-title":"Metabolic and cardiovascular adverse effects associated with antipsychotic drugs","volume":"8","author":"De Hert","year":"2012","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0210","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1001\/archinternmed.2009.456","article-title":"Impact of FDA black box advisory on antipsychotic medication use","volume":"170","author":"Dorsey","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0215","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/pds.1424","article-title":"Cardiovascular risks of atypical antipsychotic drug treatment","volume":"16","author":"Drici","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0220","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/00004714-199812000-00011","article-title":"Prolongation of QT interval in isolated feline hearts by antipsychotic drugs","volume":"18","author":"Drici","year":"1998","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0225","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1097\/00005344-200306000-00016","article-title":"Risperidone prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current","volume":"41","author":"Drolet","year":"2003","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0230","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0893-133X(02)00314-7","article-title":"Effects of risperidone on the peripheral noradrenegic system in patients with schizophrenia: a comparison with clozapine and placebo","volume":"27","author":"Elman","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0235","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00213-004-1890-y","article-title":"Effects of pharmacological doses of 2-deoxyglucose on plasma catecholamines and glucose levels in patients with schizophrenia","volume":"176","author":"Elman","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0240","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/j.2042-7158.1980.tb12961.x","article-title":"The dopamine receptor antagonist domperidone is also a competitive antagonist at alpha 1-adrenoceptors","volume":"32","author":"Ennis","year":"1980","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0245","author":"FDA"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0250","author":"FDA"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0255","author":"FDA"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0260","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1517\/14740338.4.4.731","article-title":"A review of clozapine safety","volume":"4","author":"Fitzsimons","year":"2005","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0265","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1001\/archgenpsychiatry.2011.2","article-title":"Systematic review of early cardiometabolic outcomes of the first treated episode of psychosis","volume":"68","author":"Foley","year":"2011","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0270","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1007\/BF00442570","article-title":"Side effects of clozapine","volume":"99","author":"Gaertner","year":"1989","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0275","series-title":"Principles of Pharmacology","first-page":"91","article-title":"Principles of nervous system physiology and pharmacology","author":"Galanter","year":"2008"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0280","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1176\/ajp.156.8.1270","article-title":"Clozapine-associated elevation in serum triglycerides","volume":"156","author":"Gaulin","year":"1999","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0285","first-page":"382","article-title":"Elevated serum triglycerides on clozapine resolve with risperidone","volume":"15","author":"Ghaeli","year":"1995","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0290","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/j.1476-5381.1964.tb01606.x","article-title":"An investigation of the adrenergic blocking action of chlorpromazine","volume":"23","author":"Gokhale","year":"1964","journal-title":"Br J Pharmacol Chemother"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0295","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/BF00500968","article-title":"Effect of butyrophenones on the sympathetic nerves of the isolated rabbit heart and on the postsynaptic alpha-adrenoceptors of the isolated rabbit aorta","volume":"300","author":"Gothert","year":"1977","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0300","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1093\/schbul\/sbp037","article-title":"Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trial","volume":"37","author":"Grootens","year":"2011","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0305","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1161\/01.ATV.0000111245.75752.C6","article-title":"Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute\/American Heart Association conference on scientific issues related to definition","volume":"24","author":"Grundy","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0310","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2165\/00002018-200730010-00005","article-title":"Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993\u20132003","volume":"30","author":"Haas","year":"2007","journal-title":"Drug Saf"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0315","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s11906-011-0191-1","article-title":"Sympathetic neural mechanisms in human blood pressure regulation","volume":"13","author":"Hart","year":"2011","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0320","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1177\/0269881108091254","article-title":"Cardiovascular variability during treatment with haloperidol, olanzapine or risperidone in recent-onset schizophrenia","volume":"23","author":"Hempel","year":"2009","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0325","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1001\/archpsyc.62.1.19","article-title":"Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis","volume":"62","author":"Henderson","year":"2005","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0330","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1176\/appi.ajp.157.6.975","article-title":"Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study","volume":"157","author":"Henderson","year":"2000","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0335","doi-asserted-by":"crossref","first-page":"686","DOI":"10.4088\/JCP.v65n0514","article-title":"Clozapine and hypertension: a chart review of 82 patients","volume":"65","author":"Henderson","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0340","first-page":"68","article-title":"Clozapine and myocarditis: a case series from the New Zealand Intensive Medicines Monitoring Programme","volume":"121","author":"Hill","year":"2008","journal-title":"N Z Med J"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0345","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1345\/aph.16185","article-title":"Sudden cardiac death with clozapine and sertraline combination","volume":"35","author":"Hoehns","year":"2001","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0350","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1592\/phco.21.9.871.34565","article-title":"Torsades de pointes associated with chlorpromazine: case report and review of associated ventricular arrhythmias","volume":"21","author":"Hoehns","year":"2001","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0355","first-page":"433","article-title":"A translational research approach to poor treatment response in patients with schizophrenia: clozapine-antipsychotic polypharmacy","volume":"34","author":"Honer","year":"2009","journal-title":"J Psychiatry Neurosci"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0360","doi-asserted-by":"crossref","first-page":"699","DOI":"10.2165\/00023210-200721090-00001","article-title":"Conceptual and methodological issues in the design of clinical trials of antipsychotics for the treatment of schizophrenia","volume":"21","author":"Honer","year":"2007","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0365","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0014-2999(97)01242-9","article-title":"The antipsychotic drug sertindole is a specific inhibitor of alpha1A-adrenoceptors in rat mesenteric small arteries","volume":"336","author":"Ipsen","year":"1997","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0370","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.nurx.2005.12.003","article-title":"How antipsychotics work\u2014from receptors to reality","volume":"3","author":"Kapur","year":"2006","journal-title":"NeuroRx"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0375","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0008-6363(01)00509-0","article-title":"Rapid component I(Kr) of the guinea-pig cardiac delayed rectifier K(+) current is inhibited by beta(1)-adrenoreceptor activation, via cAMP\/protein kinase A-dependent pathways","volume":"53","author":"Karle","year":"2002","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0380","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.4088\/JCP.09l05262","article-title":"Sudden cardiac death in users of second-generation antipsychotics","volume":"70","author":"Karlsson","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0385","series-title":"Basic & Clinical Pharmacology","first-page":"75","article-title":"Introduction to autonomic pharmacology","author":"Katzung","year":"2004"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0390","first-page":"546","article-title":"Thioridazine hydrochloride (Mellaril): its effect on the electrocardiogram and a report of two fatalities with electrocardiographic abnormalities","volume":"89","author":"Kelly","year":"1963","journal-title":"Can Med Assoc J"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0395","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1016\/S0140-6736(99)10385-4","article-title":"Myocarditis and cardiomyopathy associated with clozapine","volume":"354","author":"Kilian","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0400","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/7854_2010_47","article-title":"Antipsychotic drug development","volume":"4","author":"Kim","year":"2010","journal-title":"Curr Top Behav Neurosci"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0405","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1601-5215.2011.00549.x","article-title":"Relationship between heart rate variability and the severity of psychotic symptoms in schizophrenia","volume":"23","author":"Kim","year":"2011","journal-title":"Acta Neuropsych"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0410","doi-asserted-by":"crossref","first-page":"92","DOI":"10.4088\/JCP.v62n0204","article-title":"Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia","volume":"62","author":"Kinon","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0415","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1213\/01.ane.0000195441.14929.6d","article-title":"Augmented activity of adenosine triphosphate-sensitive K+ channels induced by droperidol in the rat aorta","volume":"102","author":"Kinoshita","year":"2006","journal-title":"Anesth Analg"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0420","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0014-2999(02)02074-5","article-title":"A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs","volume":"450","author":"Kongsamut","year":"2002","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0425","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/sj.npp.1300027","article-title":"H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs","volume":"28","author":"Kroeze","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0430","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJM200107193450317","article-title":"Myocarditis and cardiomyopathy associated with clozapine use in the United States","volume":"345","author":"La Grenade","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0435","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/YCO.0b013e32835035ca","article-title":"Life expectancy and cardiovascular mortality in persons with schizophrenia","volume":"25","author":"Laursen","year":"2012","journal-title":"Curr Opin Psychiatry"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0440","doi-asserted-by":"crossref","first-page":"190","DOI":"10.5694\/j.1326-5377.2009.tb02345.x","article-title":"Clozapine-induced cardiotoxicity: a clinical update","volume":"190","author":"Layland","year":"2009","journal-title":"Med J Aust"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0445","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1097\/00005344-200405000-00014","article-title":"Block of HERG human K(+) channel and IKr of guinea pig cardiomyocytes by chlorpromazine","volume":"43","author":"Lee","year":"2004","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0450","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s11517-008-0326-y","article-title":"Ventricular arrhythmias and changes in heart rate preceding ventricular tachycardia in patients with an implantable cardioverter defibrillator","volume":"46","author":"Lerma","year":"2008","journal-title":"Med Biol Eng Comput"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0455","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1017\/S1461145705005250","article-title":"QTc interval prolongation and antipsychotic drug treatments: focus on sertindole","volume":"8","author":"Lindstrom","year":"2005","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0460","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1001\/archpsyc.58.12.1172","article-title":"Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach","volume":"58","author":"Lund","year":"2001","journal-title":"Arch Gen Psychiatry"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2012.04.003_bb0465","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/hup.915","article-title":"Cardiac side effects of psychiatric drugs","volume":"23","author":"Mackin","year":"2008","journal-title":"Hum Psychopharmacol"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0470","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1017\/S1092852900022264","article-title":"Low heart rate variability is not caused by typical neuroleptics in schizophrenia patients","volume":"7","author":"Malaspina","year":"2002","journal-title":"CNS Spectr"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0475","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1152\/ajplegacy.1962.203.6.1120","article-title":"Mechanism of cardiac arrhythmias induced by diencephalic stimulation","volume":"203","author":"Manning","year":"1962","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0480","doi-asserted-by":"crossref","first-page":"H1923","DOI":"10.1152\/ajpheart.00288.2005","article-title":"Correlation between mRNA levels and functional role of alpha1-adrenoceptor subtypes in arteries: evidence of alpha1L as a functional isoform of the alpha1A-adrenoceptor","volume":"289","author":"Marti","year":"2005","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0485","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/cvr\/28.5.700","article-title":"Receptor mediated presynaptic modulation of the release of noradrenaline in human papillary muscle","volume":"28","author":"Matk\u00f3","year":"1994","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0490","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.schres.2005.07.014","article-title":"Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III","volume":"80","author":"McEvoy","year":"2005","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0495","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3810\/pgm.2010.05.2143","article-title":"Management of cardiovascular risk associated with insulin resistance, diabetes, and the metabolic syndrome","volume":"122","author":"Mehta","year":"2010","journal-title":"Postgrad Med"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0500","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.4088\/JCP.10m05997","article-title":"A 12-month randomized, open-label study of the metabolic effects of olanzapine and risperidone in psychotic patients: influence of valproic acid augmentation","volume":"72","author":"Meltzer","year":"2011","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0505","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.coph.2011.02.007","article-title":"The role of serotonin receptors in the action of atypical antipsychotic drugs","volume":"11","author":"Meltzer","year":"2011","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0510","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.clinthera.2010.03.003","article-title":"Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: a randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder","volume":"32","author":"Miceli","year":"2010","journal-title":"Clin Ther"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0515","first-page":"135","article-title":"the role of differential blockade of alpha-adrenergic agonists in chlorpromazine-induced hypotension","volume":"247","author":"Morgan","year":"1980","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0520","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/da.10037","article-title":"Effects of olanzapine and clozapine upon pulse rate variability","volume":"16","author":"Mueck-Weymann","year":"2002","journal-title":"Depress Anxiety"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0525","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1476-5381.1988.tb11401.x","article-title":"Effect of chlorpromazine on sympathetic neuroeffector transmission in the rabbit isolated pulmonary artery and aorta","volume":"93","author":"Nedergaard","year":"1988","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0530","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1001\/archpsyc.59.4.337","article-title":"Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia","volume":"59","author":"Newcomer","year":"2002","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0535","doi-asserted-by":"crossref","first-page":"473","DOI":"10.2165\/11587800-000000000-00000","article-title":"Assessing QT interval prolongation and its associated risks with antipsychotics","volume":"25","author":"Nielsen","year":"2011","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0540","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00213-007-1064-9","article-title":"Orthostatic hypotensive effect of antipsychotic drugs in Wistar rats by in vivo and in vitro studies of alpha(1)-adrenoceptor function","volume":"199","author":"Nourian","year":"2008","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0545","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejphar.2008.08.014","article-title":"The antagonistic effect of antipsychotic drugs on a HEK293 cell line stably expressing human alpha1A1-adrenoceptors","volume":"596","author":"Nourian","year":"2008","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0550","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1097\/01.anes.0000281893.39781.64","article-title":"Does low-dose droperidol administration increase the risk of drug-induced QT prolongation and torsade de pointes in the general surgical population?","volume":"107","author":"Nuttall","year":"2007","journal-title":"Anesthesiology"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0555","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1192\/apt.9.6.414","article-title":"Psychotropic medication and the heart","volume":"9","author":"O'Brien","year":"2003","journal-title":"Adv Psychiatr Treat"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0560","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1001\/archpsyc.64.2.242","article-title":"Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's general practice research database","volume":"64","author":"Osborn","year":"2007","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0565","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0163-7258(01)00138-3","article-title":"Autonomic control of the venous system in health and disease: effects of drugs","volume":"90","author":"Pang","year":"2001","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0570","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/BF01250044","article-title":"Chronic haloperidol and adrenergic receptor sensitivity in the rat","volume":"57","author":"Perrington","year":"1983","journal-title":"J Neural Transm"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0575","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/0014-2999(81)90443-X","article-title":"Pre- and postsynaptic alpha-adrenoceptor antagonism by neuroleptics in vivo","volume":"69","author":"Petersen","year":"1981","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0580","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1192\/bjp.166.6.712","article-title":"Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group","volume":"166","author":"Peuskens","year":"1995","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0585","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1046\/j.0306-5251.2001.01448.x","article-title":"Comparison of clozapine and haloperidol on some autonomic and psychomotor functions, and on serum prolactin concentration, in healthy subjects","volume":"52","author":"Pretorius","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0590","doi-asserted-by":"crossref","first-page":"566","DOI":"10.4088\/JCP.08m04912gre","article-title":"Persistent antipsychotic polypharmacy and excessive dosing in the community psychiatric treatment setting: a review of medication profiles in 435 Canadian outpatients","volume":"71","author":"Procyshyn","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0595","first-page":"331","article-title":"Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatment","volume":"32","author":"Procyshyn","year":"2007","journal-title":"J Psychiatry Neurosci"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0600","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/YCO.0b013e32833f46c9","article-title":"Cardiovascular aspects of antipsychotics","volume":"23","author":"Raedler","year":"2010","journal-title":"Curr Opin Psychiatry"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0605","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJMoa0806994","article-title":"Atypical antipsychotic drugs and the risk of sudden cardiac death","volume":"360","author":"Ray","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0610","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/qjmed\/hci018","article-title":"Heart rate variability measurements and the prediction of ventricular arrhythmias","volume":"98","author":"Reed","year":"2005","journal-title":"QJM"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0615","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S0140-6736(00)02035-3","article-title":"QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients","volume":"355","author":"Reilly","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0620","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1192\/bjp.180.6.515","article-title":"Thioridazine and sudden unexplained death in psychiatric in-patients","volume":"180","author":"Reilly","year":"2002","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0625","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1080\/j.1440-1614.2004.01481.x","article-title":"Clozapine-related myocarditis and cardiomyopathy in an Australian metropolitan psychiatric service","volume":"38","author":"Reinders","year":"2004","journal-title":"Aust N Z J Psychiatry"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0630","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2165\/11530250-000000000-00000","article-title":"Progress in defining optimal treatment outcome in schizophrenia","volume":"24","author":"Remington","year":"2010","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0635","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.pharmthera.2009.10.010","article-title":"Metabolic side effects of antipsychotic drug treatment\u2014pharmacological mechanisms","volume":"125","author":"Reynolds","year":"2010","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0640","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1176\/appi.ajp.159.9.1607-a","article-title":"Myocarditis with quetiapine","volume":"159","author":"Roesch-Ely","year":"2002","journal-title":"Am J Psychiatry"},{"issue":"2\u20133","key":"10.1016\/j.pharmthera.2012.04.003_bb0645","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.schres.2010.07.012","article-title":"Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis","volume":"123","author":"Rummel-Kluge","year":"2010","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0650","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1038\/sj.npp.1301541","article-title":"Effects of olanzapine and ziprasidone on glucose tolerance in healthy volunteers","volume":"33","author":"Sacher","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0655","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1007\/BF01273320","article-title":"Blood biogenic amines during clozapine treatment of early-onset schizophrenia","volume":"104","author":"Schulz","year":"1997","journal-title":"J Neural Transm"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0660","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S0006-3223(98)00199-1","article-title":"Risperidone-induced increase of plasma norepinephrine is not correlated with symptom improvement in chronic schizophrenia","volume":"45","author":"See","year":"1999","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0665","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1177\/026988110201600410","article-title":"The potential cardiotoxicity of antipsychotic drugs as assessed by heart rate variability","volume":"16","author":"Silke","year":"2002","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0670","first-page":"459","article-title":"Postural hypotension in chronically medicated schizophrenics","volume":"51","author":"Silver","year":"1990","journal-title":"J Clin Psychiatry"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2012.04.003_bb0675","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1177\/10742484050100i402","article-title":"Beta-adrenergic blockers as antiarrhythmic and antifibrillatory compounds: an overview","volume":"10","author":"Singh","year":"2005","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0680","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1017\/S1461145711001271","article-title":"Olanzapine, but not aripiprazole, weight-independently elevates serum triglycerides and activates lipogenic gene expression in female rats","volume":"15","author":"Skrede","year":"2012","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0685","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.schres.2009.07.011","article-title":"Clozapine and quetiapine acutely reduce glucagon-like peptide-1 production and increase glucagon release in obese rats: implications for glucose metabolism and food choice behaviour","volume":"115","author":"Smith","year":"2009","journal-title":"Schizophr Res"},{"issue":"4","key":"10.1016\/j.pharmthera.2012.04.003_bb0690","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3109\/13813455.2011.576681","article-title":"Olanzapine effects on body composition, food preference, glucose metabolism and insulin sensitivity in the rat","volume":"117","author":"Smith","year":"2011","journal-title":"Arch Physiol Biochem"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0695","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.schres.2008.12.013","article-title":"Predictors of starting to smoke cigarettes in patients with first episode psychosis","volume":"108","author":"Smith","year":"2009","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0700","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/00002826-199903000-00006","article-title":"The impact of clozapine treatment on serum lipids in chronic schizophrenic patients","volume":"22","author":"Spivak","year":"1999","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0705","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1080\/j.1440-1665.2004.02156.x","article-title":"Severe tachycardia following low-dose clozapine treatment","volume":"13","author":"Stampfer","year":"2005","journal-title":"Australas Psychiatry"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0710","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1111\/j.1540-8167.2008.01232.x","article-title":"Novel measures of heart rate variability predict cardiovascular mortality in older adults independent of traditional cardiovascular risk factors: the Cardiovascular Health Study (CHS)","volume":"19","author":"Stein","year":"2008","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0715","series-title":"Essentials of Schizophrenia","first-page":"173","article-title":"Pharmacotherapies","author":"Stroup","year":"2012"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0720","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1176\/appi.ajp.2011.10111609","article-title":"A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP)","volume":"168","author":"Stroup","year":"2011","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0725","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1006\/taap.2001.9168","article-title":"In vivo canine model comparison of cardiohemodynamic and electrophysiological effects of a new antipsychotic drug aripiprazole (OPC-14597) to haloperidol","volume":"173","author":"Sugiyama","year":"2001","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0730","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1023\/A:1020464017021","article-title":"Safety and tolerability: how do newer generation \u201catypical\u201d antipsychotics compare?","volume":"73","author":"Tandon","year":"2002","journal-title":"Psychiatr Q"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0735","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1034\/j.1600-0447.2000.101006416.x","article-title":"Atypical antipsychotics and weight gain\u2014a systematic review","volume":"101","author":"Taylor","year":"2000","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0740","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1211\/jpp.62.07.0014","article-title":"Effects of K openers on the QT prolongation induced by HERG-blocking drugs in guinea-pigs","volume":"62","author":"Testai","year":"2010","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0745","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1600-0447.2010.01563.x","article-title":"Safety of sertindole versus risperidone in schizophrenia: principal results of the sertindole cohort prospective study (SCoP)","volume":"122","author":"Thomas","year":"2010","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0750","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1592\/phco.27.2.175","article-title":"Accuracy of uncorrected versus corrected QT interval for prediction of torsade de pointes associated with intravenous haloperidol","volume":"27","author":"Tisdale","year":"2007","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0755","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1161\/01.CIR.94.11.2850","article-title":"Impact of reduced heart rate variability on risk for cardiac events","volume":"94","author":"Tsuji","year":"1996","journal-title":"The Framingham Heart Study. Circulation"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0760","doi-asserted-by":"crossref","first-page":"4666","DOI":"10.1091\/mbc.E06-05-0422","article-title":"Association of 14-3-3 proteins to beta1-adrenergic receptors modulates Kv11.1 K+ channel activity in recombinant systems","volume":"17","author":"Tutor","year":"2006","journal-title":"Mol Biol Cell"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0765","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0014-2999(03)01369-4","article-title":"Acute effects of antipsychotic drugs on cardiovascular responses to stress","volume":"464","author":"van den Buuse","year":"2003","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0770","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1152\/ajplegacy.1975.228.3.923","article-title":"Effect of posterior hypothalamic stimulation on ventricular fibrillation threshold","volume":"228","author":"Verrier","year":"1975","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0775","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.brainres.2010.05.060","article-title":"Olanzapine-induced accumulation of adipose tissue is associated with an inflammatory state","volume":"1350","author":"Victoriano","year":"2010","journal-title":"Brain Res"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0780","doi-asserted-by":"crossref","first-page":"997","DOI":"10.2165\/11318880-000000000-00000","article-title":"Proarrhythmic risk with antipsychotic and antidepressant drugs: implications in the elderly","volume":"26","author":"Vieweg","year":"2009","journal-title":"Drugs Aging"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0785","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ejphar.2008.06.088","article-title":"Clozapine-induced myocarditis: role of catecholamines in a murine model","volume":"592","author":"Wang","year":"2008","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0790","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1600-0447.1996.tb10653.x","article-title":"Electrocardiographic changes in patients receiving neuroleptic medication","volume":"93","author":"Warner","year":"1996","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0795","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0165-1838(99)00057-0","article-title":"Left stellate stimulation increases left ventricular ejection fraction in patients with essential palmar hyperhidrosis","volume":"78","author":"Wong","year":"1999","journal-title":"J Auton Nerv Syst"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0800","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1080\/15622970801910399","article-title":"Blood pressure changes during clozapine or olanzapine treatment in Korean schizophrenic patients","volume":"10","author":"Woo","year":"2009","journal-title":"World J Biol Psychiatry"},{"key":"10.1016\/j.pharmthera.2012.04.003_bb0805","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.2146\/ajhp070279","article-title":"Association of antipsychotic and antidepressant drugs with Q\u2013T interval prolongation","volume":"65","author":"Zemrak","year":"2008","journal-title":"Am J Health Syst Pharm"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725812000800?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725812000800?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T21:00:28Z","timestamp":1687554028000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725812000800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":161,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["S0163725812000800"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2012.04.003","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]}}}